New therapeutic agents for castration-refractory prostate cancer.
Patten
David Y
DY
Sartor
Oliver
O
D000736:Androstenes; D000737:Androstenols / Q000627:therapeutic use; D001549:Benzamides; D016232:Endothelins / Q000037:antagonists & inhibitors; D006801:Humans; D008297:Male; D009570:Nitriles; D009919:Orchiectomy; D010669:Phenylthiohydantoin / Q000031:analogs & derivatives / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011944:Receptors, Androgen / Q000502:physiology; D013792:Thalidomide / Q000627:therapeutic use; D014020:Tissue Extracts / Q000627:therapeutic use
D000736:Androstenes; D000737:Androstenols; D001549:Benzamides; D016232:Endothelins; D009570:Nitriles; D047428:Protein Kinase Inhibitors; D011944:Receptors, Androgen; D014020:Tissue Extracts; D010669:Phenylthiohydantoin; D013792:Thalidomide; C511774:sipuleucel-T; C540278:enzalutamide; C089740:abiraterone